Should Cochrane reviews be performed during the development of new concepts?

Human Reproduction

Volumn 27, Issue 1, 2012, Pages 6-8

  Humaidan, P ^a   Kol, S ^b   Engmann, L ^c   Benadiva, C ^c   Papanikolaou, E G ^d   Andersen, C Yding ^e  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b RAMBAM MEDICAL CENTER   (Israel)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e Mental Health Center Glostrup   (Denmark)

Author keywords

Cochrane review; GnRHa triggering; meta analysis

Indexed keywords

GONADORELIN AGONIST;

CLINICAL DEVELOPMENT PLAN; COCHRANE LIBRARY; CONCEPT ANALYSIS; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); OOCYTE MATURATION; PRACTICE GUIDELINE; REVIEW;

EID: 83755205871     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/der353     Document Type: Review

References (15)

1. Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2000;2:CD001302.
2. Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2002;2:CD001302.
3. Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2001;4:CD001750.
4. Castillo JC, Dolz M, Bienvenido E, Abad L, Casan EM, Bonilla-Musoles F. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed Online 2010;20:175-181.
5. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89:84-91.
6. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009;18:630-634.
7. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, Andersen CY. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005;20:1213-1220. (Pubitemid 40796107)
8. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006;13:173-178. (Pubitemid 44207763)
9. Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010;93:847-854.
10. Humaidan P, Kol S, Papanikolaou EG on behalf of The Copenhagen GnRH agonist TriggeringWorkshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change in practice? Hum Reprod Update 2011 (in press).
11. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005;20:2887-2892. (Pubitemid 41508652)
12. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12:651-671. (Pubitemid 44605507)
13. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant LH, when a GnRH-Agonist is used instead of HCG for ovulation triggering. A randomized prospective proof of concept study. Fertil Steril 2011;95:1174-1177.
14. Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and meta-analysis. Fertil Steril 2011;95:188-196.
15. Youssef MAFM, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev 2010;11:CD008046.